Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials by Hong, David S, Prof, DuBois, Steven G, MD, Kummar, Shivaani, Prof, Farago, Anna F, MD, Albert, Catherine M, MD, Rohrberg, Kristoffer S, MD, van Tilburg, Cornelis M, MD, Nagasubramanian, Ramamoorthy, MD, Berlin, Jordan D, Prof, Federman, Noah, Prof, Mascarenhas, Leo, MD, Geoerger, Birgit, MD, Dowlati, Afshin, Prof, Pappo, Alberto S, Prof, Bielack, Stefan, MD, Doz, François, Prof, McDermott, Ray, MD, Patel, Jyoti D, Prof, Schilder, Russell J, Prof, Tahara, Makoto, MD, Pfister, Stefan M, MD, Witt, Olaf, Prof, Ladanyi, Marc, Prof, Rudzinski, Erin R, MD, Nanda, Shivani, MS, Childs, Barrett H, MD, Laetsch, Theodore W, MD, Hyman, David M, MD, Drilon, Alexander, MD

Get full text

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial by Konstantinopoulos, Panagiotis A, MD, Cheng, Su-Chun, ScD, Wahner Hendrickson, Andrea E, MD, Penson, Richard T, MD, Schumer, Susan T, MD, Doyle, L Austin, Prof, Lee, Elizabeth K, MD, Kohn, Elise C, Prof, Duska, Linda R, Prof, Crispens, Marta A, Prof, Olawaiye, Alexander B, MD, Winer, Ira S, MD, Barroilhet, Lisa M, MD, Fu, Siqing, Prof, McHale, Michael T, Prof, Schilder, Russell J, Prof, Färkkilä, Anniina, MD, Chowdhury, Dipanjan, Prof, Curtis, Jennifer, MS, Quinn, Roxanne S, BSc, Bowes, Brittany, BSc, D'Andrea, Alan D, Prof, Shapiro, Geoffrey I, Prof, Matulonis, Ursula A, Prof

Get full text